Ly6g pe vio770

Manufactured by Miltenyi Biotec

The Ly6g-PE-Vio770 is a fluorochrome-conjugated antibody that binds to the Ly6g antigen. It is designed for use in flow cytometry applications to identify and quantify Ly6g-positive cells within a sample.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

Ly6G-PE (3 citations)

2 protocols using ly6g pe vio770

Flow Cytometric Tumor Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

For flow cytometric analysis, tumor samples (n = 5) were explanted at the end of treatments, and dissociated using tumor dissociation kit mouse (catalog no. 130-096-730, Miltenyi Biotec) according to manufacturer's instructions. iCAF and myCAF subpopulations were addressed using the following antibodies: CD45-APC-Vio770 (REA737), CD326/EpCAM-APC (REA977), Ly6c-FITC (REA796; Miltenyi Biotec), and Pdpn-PE (127407; BioLegend). MDSCs and CD8 phenotype were evaluated with the following antibodies: CD45-APC-Vio770 (REA737), CD11b-APC (REA592), Ly6c-FITC (REA796), Ly6g-PE-Vio770 (REA526), CD3-PerCP-Vio700 (REA641), CD8-Vioblue (REAL187), CD178 Pe-Vio615 (REA1171) and the Fixable die Viobility 405/520, all from Miltenyi Biotec. Acquisition was performed using Becton Dickinson LSR-Fortessa X-20, and samples were analyzed with FlowJo software (TreeStar Inc.).

Pietrobono S., Sabbadini F., Bertolini M., Mangiameli D., De Vita V., Fazzini F., Lunardi G., Casalino S., Scarlato E., Merz V., Zecchetto C., Quinzii A., Di Conza G., Lahn M, & Melisi D. (2023). Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma. Cancer Research, 84(1), 118-132.

+ Open protocol

+ Expand

Multicolor Flow Cytometry of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibody reagents were obtained from Miltenyi Biotech: REA clones of antimouse CD3-APC-Vio770 (REA606), CD4-Vioblue (REA 604), CD8a-PE-Vio770 (REA 601), Foxp3-Vio515 (REA 788), NKp46-APC (REA 815), CD11c-PE (REA 754), CD11b-APC-Vio770 (REA 592), Ly6C-Vioblue (REA 796), Ly6G-PE-Vio770 (REA 526). Foxp3 staining was performed using Foxp3 Staining Buffer Set (Miltenyi Biotech).
Flow cytometry analysis was performed using a Miltenyi 8-color MACSQuant, and data were analyzed using Flowlogic (Miltenyi Biotech).

Lantier L., Poupée-Beaugé A., di Tommaso A., Ducournau C., Epardaud M., Lakhrif Z., Germon S., Debierre-Grockiego F., Mévélec M.N., Battistoni A., Coënon L., Deluce-Kakwata-Nkor N., Velge-Roussel F., Beauvillain C., Baranek T., Lee G.S., Kervarrec T., Touzé A., Moiré N, & Dimier-Poisson I. (2020). Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer. Journal for Immunotherapy of Cancer, 8(2), e001242.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!